231 related articles for article (PubMed ID: 24026082)
1. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
2. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
3. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
6. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.
Vaughan AT; Iriyama C; Beers SA; Chan CH; Lim SH; Williams EL; Shah V; Roghanian A; Frendéus B; Glennie MJ; Cragg MS
Blood; 2014 Jan; 123(5):669-77. PubMed ID: 24227819
[TBL] [Abstract][Full Text] [Related]
8. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
[TBL] [Abstract][Full Text] [Related]
9. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
10. CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.
Crow AR; Amash A; Lazarus AH
Transfusion; 2015 Jun; 55(6 Pt 2):1492-500. PubMed ID: 25496771
[TBL] [Abstract][Full Text] [Related]
11. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis.
Xiang Z; Cutler AJ; Brownlie RJ; Fairfax K; Lawlor KE; Severinson E; Walker EU; Manz RA; Tarlinton DM; Smith KG
Nat Immunol; 2007 Apr; 8(4):419-29. PubMed ID: 17322888
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
13. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
14. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
16. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
17. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.
Rankin CT; Veri MC; Gorlatov S; Tuaillon N; Burke S; Huang L; Inzunza HD; Li H; Thomas S; Johnson S; Stavenhagen J; Koenig S; Bonvini E
Blood; 2006 Oct; 108(7):2384-91. PubMed ID: 16757681
[TBL] [Abstract][Full Text] [Related]
18. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis.
Wijngaarden S; van de Winkel JG; Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Rheum; 2004 Dec; 50(12):3878-87. PubMed ID: 15593228
[TBL] [Abstract][Full Text] [Related]
19. Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
Lu H; Molony RD; Chen D; Jang S; Wolf B; Ewert S; Flaherty M; Xu F; Isim S; Shim Y; Dornelas C; Balke N; Leber XC; Scharenberg M; Koelln J; Choi E; Ward R; Johnson J; Calzascia T; Isnardi I; Williams JA; Lindenbergh PL; van de Donk NWCJ; Mutis T; Huet H; Lees E; Meyer MJ
Mol Cancer Ther; 2020 Oct; 19(10):2089-2104. PubMed ID: 32847974
[TBL] [Abstract][Full Text] [Related]
20. Antinucleosome autoantibodies bind directly to cell lines in vitro and via the FcgammaRIIB receptor to B lymphocytes in vivo: a role for immune complexes in interactions between antinucleosome IgG2a and B cells of BXSB lupus mice.
Li X; Egorina E; Bertelsen EL; Dahlen H; Hannestad K
Scand J Immunol; 2004; 60(1-2):121-33. PubMed ID: 15238081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
